Ezaladcigene resoparvovec
- Generic Name
- Ezaladcigene resoparvovec
- Drug Type
- Biotech
- CAS Number
- 2226647-27-2
- Unique Ingredient Identifier
- 2WRS0PE04O
VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)
Phase 1
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Other: Sham (Placebo) Surgery
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 14
- Registration Number
- NCT03562494
- Locations
- 🇺🇸
UC Irvine, Irvine, California, United States
🇺🇸University of Philadelphia, Dept of Neurology, Philadelphia, Pennsylvania, United States
🇺🇸Northwestern Medical Faculty Foundation, Chicago, Illinois, United States
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
Phase 1
Completed
- Conditions
- Idiopathic Parkinson's DiseaseParkinson's DiseaseBasal Ganglia DiseaseBrain DiseasesCentral Nervous System DiseasesMovement DisordersNervous System DiseasesNeurodegenerative DiseasesParkinsonian Disorders
- Interventions
- First Posted Date
- 2017-02-27
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 16
- Registration Number
- NCT03065192
- Locations
- 🇺🇸
University of California, San Francisco (UCSF), San Francisco, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath